title: Carboplatin pharmacokinetics in a patient receiving hemodialysis.
abstract: With refinements and advances in hemodialysis techniques, survival for patients with end-stage renal disease has improved significantly. To our knowledge, however, no prospective trials have been performed in patients receiving hemodialysis who are also diagnosed with cancer and are candidates for chemotherapy. We describe a 73-year-old man who was diagnosed with high-grade neuroendocrine carcinoma, metastatic to the bone and lymph nodes, and was undergoing hemodialysis. Although cisplatin is more commonly used in the treatment of metastatic neuroendocrine cancers, it may not be the best option in patients who suffer from renal insufficiency. Carboplatin is a second-generation, nonnephrotoxic platinum analog that can be hemodialyzed, although no formal guidelines are available regarding the dosing for patients receiving hemodialysis. This case describes a patient who was treated with five cycles of combination carboplatin 115 mg/m(2) on day 1 and etoposide 50 mg/m(2) on day 1 and day 3 of a 28-day cycle. Dialysis was performed for 3.5 hours starting 90 minutes after completion of carboplatin on day 1. Pharmacokinetic assessments were performed at 1, 2, 4, and 12 hours after chemotherapy infusion on day 1 of cycle 1. Total carboplatin concentrations in plasma and platinum ultrafiltrate were measured. The plasma concentration of free platinum at the end of the infusion was 31,000 ng/ml, and the area under the plasma concentration-time curve was 2.9 minute·mg/ml. No significant carboplatin-related toxicities were reported. This case report indicates that carboplatin can be safely administered in patients receiving hemodialysis.
authors.affiliation: Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Mei Ka
authors.initials: MK
authors.lastname: Fong
authors.forename: Gerald J
authors.initials: GJ
authors.lastname: Fetterly
authors.forename: Lori J
authors.initials: LJ
authors.lastname: McDougald
authors.forename: Renuka V
authors.initials: RV
authors.lastname: Iyer
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D006435:Renal Dialysis
chemical_list: D005047:Etoposide; D016190:Carboplatin
keywords: carboplatin; chemotherapy; dialysis; oncology; pharmacokinetics, neuroendocrine
references.citation: Bull Cancer. 2001 Aug;88 Spec No:S14-9
references.pmid: 11567909
references.citation: Br J Cancer. 1996 Mar;73(6):776-80
references.pmid: 8611379
references.citation: Nephrol Dial Transplant. 1997 Jan;12(1):137-40
references.pmid: 9027788
references.citation: Cancer Res. 1986 Apr;46(4 Pt 2):1972-9
references.pmid: 3512077
references.citation: Ann Oncol. 2004 Jan;15(1):51-4
references.pmid: 14679119
references.citation: Am J Med Sci. 2007 Aug;334(2):115-24
references.pmid: 17700201
references.citation: J Thorac Oncol. 2008 Sep;3(9):1073-5
references.pmid: 18758316
references.citation: Cancer Res. 1984 Nov;44(11):5432-8
references.pmid: 6386150
references.citation: Gan To Kagaku Ryoho. 1993 Dec;20(15):2409-11
references.pmid: 8259862
references.citation: Cancer Chemother Pharmacol. 1982;7(2-3):141-5
references.pmid: 7083454
references.citation: Cancer Chemother Pharmacol. 1990;27(3):234-8
references.pmid: 2176133
references.citation: J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):357-60
references.pmid: 9703013
references.citation: J Clin Oncol. 1989 Nov;7(11):1748-56
references.pmid: 2681557
references.citation: Intern Med. 2010;49(12):1179-83
references.pmid: 20558939